Exelixis sells cancer drug Cabometyx.
Exelixis, Inc. (EXEL) is expected to report earnings on Tuesday, November 3, 2026, after the close. Estimated release time 16:09 ET. Consensus EPS estimate is $0.88.
| Report date | Quarter | EPS est. | EPS actual | Surprise | Revenue |
|---|---|---|---|---|---|
| 2026-05-05 | Apr 2026 qtr | $0.77 | $0.81 | +5.9% | $610.81M |
| 2026-02-10 | Jan 2026 qtr | $0.77 | $0.91 | — | $598.66M |
| 2025-11-04 | Oct 2025 qtr | $0.69 | $0.72 | +5.1% | $597.75M |
| 2025-07-28 | Jul 2025 qtr | $0.65 | $0.68 | +4.6% | $568.26M |
| 2025-05-13 | Apr 2025 qtr | $0.36 | $0.57 | — | $555.45M |
| 2025-02-11 | Dec 2024 qtr | $0.51 | $0.48 | -5.9% | $566.75M |
| 2024-10-29 | Sep 2024 qtr | $0.35 | $0.41 | — | $539.54M |
| 2024-08-06 | Jun 2024 qtr | $0.30 | $0.78 | — | $637.18M |
EXEL has beaten consensus EPS in 3 of its last 4 scored quarters.
See EXEL on the live calendar →